Rx Product News (October 2014)

Pharmacy Times, October 2014 Diabetes, Volume 80, Issue 10

Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc

Indication: The FDA has approved Pradaxa (dabigatran etexilate mesylate) for treatment, and reduction in the risk of recurrence, of deep venous thrombosis and pulmonary embolism. For these indications, patients with a creatinine clearance rate of >30 mL/min should take 150 mg by mouth twice daily, after 5 to 10 days of parenteral anticoagulation. Pradaxa is also indicated for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Dosage Form: Capsules: 75 and 150 mg

For More Information: www.pradaxa.com

Ryanodex

Marketed by: Eagle Pharmaceuticals, Inc

Indication: The FDA has approved Ryanodex (dantrolene sodium) for the treatment of malignant hyperthermia. For this indication, Ryanodex should be administered by intravenous (IV) push at a minimum of 1 mg/kg. If signs continue, additional IV boluses should be administered up to a maximum cumulative dose of 10 mg/kg. Ryanodex is also indicated for the prevention of malignant hyperthermia in patients who are at high risk for it.

Dosage Form: Injectable suspension: 250 mg of lyophilized powder in a single-use vial for reconstitution

For More Information: www.ryanodex.com

Eylea

Marketed by: Regeneron Pharmaceuticals, Inc

Indication: The FDA has approved Eylea (aflibercept) for the treatment of diabetic macular edema. The recommended dosage for this indication is 2 mg (0.05 mL) administered by intravitreal injection every 4 weeks for the first 5 injections, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks. Eylea is also indicated for treating (1) neovascular (wet) age-related macular degeneration and (2) macular edema following central retinal vein occlusion.

Dosage Form: Single-use vial: 40 mg/ mL solution for intravitreal injection

For More Information: www.eylea.us

Seroquel XR

Marketed by: AstraZeneca

Indication: Seroquel XR (quetiapine fumarate) is an atypical antipsychotic indicated for the treatment of (1) schizophrenia; (2) bipolar I disorder, manic or mixed episodes; (3) bipolar disorder, depressive episodes; and (4) major depressive disorder, adjunctive therapy with antidepressants. The recommended dosage is once daily, preferably in the evening. The tablets should be swallowed whole without food or with a light meal.

Dosage Form: Extended-release tablets: 50, 150, 200, 300, and 400 mg

For More Information: www.seroquelxr.com